#Molecular oncology

[mplnet]

How Can Cytogenomics Help Solve Women's Health Challenges?

Have you ever asked yourself why a particular health condition occurs more often in women than in men? Why does a specific treatment work for one woman and not another? Perhaps it is in your genes. Cytogenomics is the study of how genes work in cells, and it has opened entirely new doors to women's health care. But just how could this science make a difference in your life?

Understanding Cytogenetic

Cytogenomics is the amalgamation of cytology, the science of cells, and genomics, the study of genes. It examines the way in which genes operate within a cell and how that manner influences health. This field is changing the way doctors observe Women's Health.

The Power of Precision:- This, in turn, allows doctors to have a better understanding of what is occurring inside the body level. That is, they can detect diseases at an earlier stage so that developing proper treatment plans for you can be initiated. It's almost like having a microscope that zooms on the problems at a cellular level.

Personalized Medicine: Every woman is unique in her own way, and so are her healthcare needs. Cytogenomics helps doctors tailor treatments to fit each woman's unique genetic makeup. It often leads to better results and fewer side effects. It's a bit like a custom-made health plan just for you.

Cytogenomics in Action

Let's take a detailed exploration into how cytogenetic is changing the landscape of female health.

Early Detection and Treatment for Breast Cancer:- Through cytogenomic, the time for the detection of breast cancer might be significantly advanced. Which treatment options are suitable for a specific woman? This could mean better care and even an opportunity to win the battle against the disease when done better. Doctors can now diagnose the genetic manifestations of cancer before they appear observable by classical means.

Fertility and Pregnancy:- Cytogenetic may raise questions for infertile women. It can explain why, at times, women cannot get pregnant and why some doctors are often puzzled in trying to help them. In addition, it finds potential problems while pregnant so that both mom and baby have a better chance of staying healthy.

Management of Menopause: Every woman's menopausal experience is unique. Cytogenetic would tell doctors why and could help them develop customized symptom-management plans. That's like having a roadmap for this great change in life.

Making Sure It Works: The Importance of Validation

Of course, any new medical approach needs to be tested thoroughly. That's where Validation comes in. Scientists run many tests to ensure that cytogenetic techniques are accurate and reliable.

This step is crucial. It ensures that the results are trustworthy when your doctor uses cytogenetics to help you. Validation gives both doctors and patients confidence in the science. It's like double-checking your work to make sure everything adds up.

Conclusion

So, what does all this mean for you? It means better health care tailored just for you. It means answers to questions you might have had about your health for years. And it means hope for better treatments for conditions that affect women.

As cytogenetic advances, it's paving the way for a new era in women's health. This field transforms how we approach women's health challenges from more accurate diagnoses to more effective treatments.

Cytogenetics is a groundbreaking science that examines the smallest parts of our bodies, our cells, and genes – helping solve big health problems. Thanks to this, the future of women's health looks brighter than ever. Read More.

[heardatmedschool]

“When no one knows the mechanism, we always blame cytokines.”

About the pro-thrombotic tendencies of most neoplasms.

[science-sculpt]

A Dive into CAR-T Cell Therapy

Imagine training your own soldiers to fight cancer. Not just any soldiers, but elite warriors genetically modified to recognize and demolish the enemy with laser-like precision. That's the essence of CAR-T cell therapy, a revolutionary approach turning heads in the medical world. In the fight against cancer, CAR-T cell therapy embodies this very concept, harnessing the body's own immune system to wage war against malignant cells. T cells are the special forces of your immune system, constantly scanning for and eliminating threats. But sometimes, cancer cells outsmart them, hiding in plain sight. CAR-T cell therapy steps in, equipping these T-cells with a unique weapon: a Chimeric Antigen Receptor (CAR). Think of it as a GPS that locks onto a specific protein on cancer cells, guiding the T-cells straight to their target.

How does it work? Here's the simplified version:

Recruitment: First, T cells are extracted from your blood. Modification Station: In the lab, scientists use a virus or other tools to insert the CAR gene into the T cells' DNA. This equips them with the cancer-targeting GPS. Bootcamp Boost: The modified T cells are grown in a special environment, multiplying into a powerful army. Redeployment: The CAR-T cell troops are infused back into your bloodstream, ready to seek and destroy.

Sounds amazing, right? But like any powerful technology, CAR-T comes with its own set of challenges. The treatment process is complex and expensive, and there can be serious side effects like cytokine release syndrome, where the immune system goes into overdrive. So, is CAR-T a miracle cure? Not yet. But for some patients with aggressive blood cancers like leukemia and lymphoma, it has shown remarkable results, offering hope where other treatments have failed. Researchers are constantly working to improve the safety and efficacy of CAR-T, making it a potential game-changer for even more cancers in the future. CAR-T cell therapy has demonstrated remarkable efficacy in the treatment of certain types of hematologic malignancies, including acute lymphoblastic leukemia (ALL) and certain subtypes of non-Hodgkin lymphoma. Clinical trials have shown unprecedented response rates and durable remissions in patients who have exhausted all other treatment options. Furthermore, ongoing research is exploring the potential of CAR-T cell therapy in treating solid tumors, extending its therapeutic reach to a broader spectrum of cancers. The future is bright for CAR-T. It's a testament to the power of human ingenuity and our ongoing quest to conquer one of humanity's greatest foes. While there's still a way to go, this groundbreaking therapy is a beacon of hope, reminding us that even the seemingly impossible can become reality.

[dssima]

Understanding Abbott Molecular Solutions: Transforming Diagnostics with DSS Image Tech

Abbott Molecular is the world leader in the field of diagnostics, providing innovative solutions and revolutionizing the detection and monitoring of diseases. DSS Image Tech is proud to collaborate with Abbott Molecular to provide state-of-the-art diagnostic technology to healthcare professionals and institutions, thereby ensuring precision, accuracy, and reliability in diagnostic testing to provide a better outcome for the patient.

What Is Abbott Molecular?

Abbott Molecular specializes in high-tech diagnostic products that are aimed at detecting and tracking genetic disorders, infectious diseases, and cancer. Through molecular technology, the solution enables healthcare providers to make rapid and accurate decisions. DSS Image Tech offers a comprehensive line of products for Abbott Molecular, with solutions tailored to meet the needs of individual labs and clinics.

Important Services of Abbott Molecular

Abbott Molecular has a portfolio that is vast, with diagnostics that deliver accuracy and speed. Some of their notable offerings are available through DSS Image Tech, including the following:

RealTime PCR Technology

Abbott's RealTime PCR systems are highly advanced and ensure reliable detection of DNA and RNA markers. These solutions are crucial in diagnosing infectious diseases and cancer.

FISH (In Situ Hybridization) Assays

Their FISH assays offer deeper insight into genetic aberrations, assisting in early detection of cancer and targeted therapies.

Oncology Diagnostics

With solid cancer detection tests, Abbott Molecular equips healthcare providers to tailor the treatment plan based on the genetic nature of the disease.

Infectious Disease Panels

Diagnostic panels from Abbott Molecular help identify infections caused by viruses and bacteria precisely, thereby leading to timely and accurate interventions.

Why DSS Image Tech for Abbott Molecular Products?

At DSS Image Tech, we bring the latest in diagnostics to our clients. That's why healthcare providers and laboratories rely on us

Trusted Partnership: Our collaboration with Abbott Molecular ensures delivery of world-class diagnostic solutions supported by expert support.

Comprehensive Product Range: We provide access to a wide range of Abbott Molecular products with specific laboratory needs in mind.

Expert Support and Training: Our professionals seamlessly integrate our Abbott Molecular technology into your workflow with easy and hands-on training for full benefit.

Quality Assurance: We practice the highest benchmarks and ensure all our products, services, fit the high-tech standards of modern diagnostics requirements.

How Abbott Molecular is Building Modern Healthcare

Beyond walls of the labs, Abbott Molecular solutions empower medical professionals to achieve:

Determine diseases at much earlier stages allowing for better probabilities.

Develop individualized treatment plans according to genetic findings.

Track the efficacy of treatments currently in place with accuracy.

By partnering with DSS Image Tech, healthcare institutions can access these transformative tools to elevate their diagnostic capabilities.

Abbott Molecular's applied technologies are changing the landscape of diagnosis with precision and speed never before seen in the detection and monitoring of disease. DSS Image Tech is proud to partner with such esteemed and sought-after solutions within laboratories and healthcare providers in the realm of cancer, infectious disease, or genetic testing, bringing both reliability and precision to healthcare professionals.

[aarunresearcher]

The United States IVD market is experiencing robust growth, driven by the increasing prevalence of chronic and infectious diseases, including diabetes, cardiovascular disorders, cancer, and infectious diseases such as COVID-19. This, in turn, has heightened the need for accurate and timely diagnostic tools like IVD, thus creating lucrative growth opportunities for the market. 

[creativeera]

Cancer Biomarkers Market Poised to Exhibit a CAGR of 7.3% by 2031

Cancer biomarkers are substances whose presence is indicative of some biological condition, processes, or pathology. They can be used for cancer diagnosis or checking effectiveness of treatment. Being non-invasive procedures, demand for cancer biomarkers is growing rapidly. They aid in early detection of cancer during screening programs and reduce cost of cancer treatment. Global cancer biomarkers market is estimated to be valued at USD 25.60 Bn in 2024 and is expected to reach USD 59.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031.

Key Takeaways Key players operating in the Cancer Biomarkers market are Schlumberger Limited, Rockwell Automation Inc., SIS-TECH Solutions LP, Emerson Electric Company, HIMA Paul Hildebrandt GmbH, Honeywell International Inc., Siemens AG, Yokogawa Electric Corporation, Schneider Electric SE, and ABB Ltd. They are investing heavily in biomarker detection methods and panels targeting unmet clinical needs. Rising incidence of cancer across the world is driving for Cancer Biomarkers Market Demand. Biomarkers help in cancer screening and detecting disease at early stages. This improves treatment outcomes and survival rates significantly. Initiatives by governments and cancer councils to spread cancer awareness are also boosting the market. Global expansion strategies adopted by leading players are expected to support market growth during the forecast period. They are expanding their footprint in emerging markets of Asia Pacific, Latin America, and Middle East & Africa to tap the high growth opportunities. This will increase access to advanced cancer diagnostic solutions. Market Key Trends The use of artificial intelligence and machine learning algorithms to discover novel biomarkers from large datasets is a key trend in the market. It helps accelerate the process of biomarker identification. Genomic and proteomic biomarkers are also gaining traction for their role in cancer detection as well as tracking cancer progression and drug response. Development of personalized diagnostics based on multi-omics approaches and liquid biopsy tests are some other trends expected to shape the market.

Porter’s Analysis Threat of new entrants: The cancer biomarkers market requires huge capital investments in R&D for developing novel biomarkers and testing kits which makes the entry difficult for new players. Bargaining power of buyers: Buyers have moderate bargaining power in this market as there are many players offering similar cancer biomarker testing services. Bargaining power of suppliers: Suppliers have low bargaining power due to availability of alternative raw material suppliers in the market. Threat of new substitutes: Substitutes have low threat as there are limited substitutes available for cancer biomarker tests. Competitive rivalry: The market is highly competitive due to presence of many global as well as regional players. Geographical Regions North America region accounts for the largest share of the cancer biomarkers market in terms of value due to presence of major players, rising healthcare expenditure and increasing prevalence of cancer in the region. Asia Pacific is expected to grow at the fastest CAGR during the forecast period owing to increasing awareness regarding cancer, improving healthcare infrastructure and rising access to diagnostic services in emerging economies of China and India in this region.

Get more insights on Cancer Biomarkers Market

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[pathologylab]

Just 2 Days to Go!

We are on the final countdown to #MedlabAsia2024! Get ready to join us at the Queen Sirikit National Convention Center, #Bangkok, from July 10–12.

Stop by Booth H6.C19 to explore our innovative products.

🚂 Medlab Asia 2024 : Queen Sirikit National Convention Center, Bangkok

📅 Date: 10th - 12th July 2024

🎯 Booth No.: H6.C19

BOOK YOUR MEETING SLOT: https://www.genes2me.com/upcoming-events

#HealthcareInnovation #MolecularDiagnostics #genes2me #nucleicacid #Exhibition #events #conventioncenter #rtpcr #ivd #BangkokEvent #conventioncenter #sirikitnationalconventioncenter #Oncology #HealthcareInnovation #MedicalTechnology #MedlabAsia #Diagnostics #LabSoluti #queensirikitnationalconventioncenter

[trendingreportz]

Molecular Oncology Market - Forecast(2024 - 2030)

Molecular Oncology Market Overview

Molecular Oncology Market size is projected to reach $3,700 million by 2026, growing at a CAGR of 6.1% over 2021-2026. Molecular oncology is the branch of medical science that helps to reduce the problems of cancer. Various tests are performed in blood for detecting DNA and RNA. Molecular oncology helps to provide a detailed information for the treatment of cancer and provide rapid results. Molecular oncology has various usage in clinical and point-of-care (POC) testing for the quick detection of cancer. Increasing prevalence of cancer owing to changing lifestyle and rising adoption of advanced technologies in order to provide detection of various kinds of cancer is the major factor driving the growth of this market. Furthermore, increasing number geriatric population and rising research and development activities is set to further enhance the overall market demand for Molecular Oncology Market for the period 2021-2026.

Molecular Oncology Market Report Coverage

The report: “Molecular Oncology Market Forecast (2021-2026)”, by IndustryARC, covers an in-depth analysis of the following segments of the Molecular Oncology Market.

By Type: Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, and Others

By Technology: In Situ Hybridization, PCR, Isothermal Nucleic Amplification, and Others

By End-Use Industry: Hospitals, Clinics, Diagnostics Centers, and Others

By Geography: North America (U.S., Canada, Mexico), Europe (U.K, Germany, Italy, France, Spain, Russia, Rest of Europe), Asia Pacific (China, Australia, Japan, South Korea, India, Rest of Asia Pacific), South America (Brazil, Argentina, Others) and Rest of the World (Middle East, Africa)

Request Sample

Key Takeaways

Geographically, in 2020, North America dominated the Molecular Oncology Market owing to growing prevalence of cancer disease, rising advancement technology for the treatment of care and rising healthcare infrastructure increases the growth in healthcare sector and are rising the growth of this region.

Increasing prevalence of cancer owing to changing lifestyle and rising adoption of advanced technologies in order to provide detection of various kinds of cancer are likely to aid in the market growth of the Molecular Oncology. 

Detailed analysis of the Strength, Weakness, and Opportunities of the prominent manufacturers operating in the market will be provided in the Molecular Oncology Market report.

High cost of molecular diagnostic testing technologies is set to create hurdles for the Molecular Oncology Market.

Molecular Oncology Segment Analysis – By Type

The Molecular Oncology Market based on Type can be further segmented into Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, and Others. The Breast Cancer segment is the major segment producing revenue in 2020. According to World Health Organization (WHO), in 2020 about 2.3 million women are diagnosed with breast cancer that increases the demand of molecular oncology diagnostics treatment and are increasing the growth of this market. The Prostate Cancer segment is estimated to register the fastest CAGR of 1.05% for the period 2021-2026. This is mainly owing to changing living lifestyle that changes the consumption patterns which increases the prostate cancer and are increasing the growth of this market. 

Inquiry Before Buying

Molecular Oncology Segment Analysis – By End-Use Industry

The Molecular Oncology Market based on End-Use Industry can be further segmented into Hospitals, Clinics, Diagnostics Centers, and Others. The Hospitals segment registers for the highest Molecular Oncology market share in 2020. This is mainly owing to availability of skilled healthcare professional, well-resourced operating & diagnostic rooms and improved hospital-based healthcare services that increases the preference of hospitals among people and are increasing the growth of this market. The Diagnostic Centers segment is forecast to register the fastest CAGR of 2% over 2021-2026. This is mainly owing to availability of advanced technology for the diagnosis of cancer that are increasing the growth of this market.

Molecular Oncology Segment Analysis – By Geography

North America dominated the Molecular Oncology Market with major share of 40% in 2020. This is owing to the growing prevalence of cancer disease, rising advancement technology for the treatment of care and rising healthcare infrastructure increases the growth in healthcare sector are rising the growth of this region. Moreover, various U.S. based companies such as, Roche Molecular Systems, Inc. are developing Cobas EGFR Mutation Test for lung cancer patients that increases development in technology and are rising the growth of this market.

However, Asia Pacific is estimated to outpace all the regions by clocking the highest CAGR of 3.05% during the forecast period 2021-2026 owing to increasing geriatric population and changing in lifestyle.

Schedule a Call

Molecular Oncology Market Drivers 

Growing Prevalence of Cancer Disease

The rising cases of cancer disease among population is a major factor that are increasing the growth of this market. According to World Health Organization, in 2020 about 10 million deaths occur owing to increasing cancer cases that increases the demand of molecular oncology testing and are rising the growth of the Molecular Oncology Market over 2021-2026.

Rising Adoption of Advanced Technologies

Increasing technological development helps for the treatment of cancer diseases that increases the demand of molecular oncology testing and are increasing the growth of this Market. Moreover, rising adoption of advanced technologies such as PCR, multiplex PCR helps to detect cancer that increasing the growth of Molecular Oncology Market over 2021-2026.

Covid-19 Impact:

COVID-19 pandemic had greatly impacted the growth of Molecular Oncology Market. Owing to pandemic, there is social distancing, remote working that reduces the supply in healthcare industry and are negatively impacted the growth of this market.

Molecular Oncology Market Challenges 

High Cost of Technologies

The factors that is set to impede the growth of the Molecular Oncology Market are the high cost of molecular diagnostics testing technologies that is set to create hurdles for the Molecular Oncology Market. 

Buy Now

Molecular Oncology Landscape

Product launches, acquisitions, collaboration, joint ventures, and geographical expansions are key strategies adopted by players in the Molecular Oncology Market. Molecular Oncology top 10 companies are Becton, Dickinson, and Company, Danaher Corporation, Roche Diagnostics, Abbott Laboratories, Cepheid, Qiagen NV, Siemens Healthineers, Bayer AG, ICON Plc, Dako, and GE Healthcare.

Developments

In February 2019, ICON plc has acquisition with MolecularMD. This acquisition enhances molecular diagnostic testing including next-generation sequencing, and immunohistochemistry (IHC).

[cbccindia]

Transforming Cancer Care with Precision Oncology

Cancer Immunotherapy stands as a source of encouragement in the landscape of cancer treatment, offering novel approaches that harness the body’s immune system to combat cancer cells. As conventional treatments like Chemotherapy have limitations and can often cause significant side effects, the emergence of Immunotherapy has sparked a new era in oncology, transforming the way we perceive and manage cancer. Let us delve into the intricacies of Cancer Immunotherapy, exploring its mechanisms, efficacy, and impact on cancer treatment, alongside the invaluable contributions of CBCC India in advancing patient care and wellbeing.

[luckydige45]

In the rapidly growing field of  The asia pacific oncology based molecular diagnostics market size was estimated at USD 645.90 million in 2023 and is projected to hit around USD 2,628.97 million by 2033, growing at a CAGR of 15.07% during the forecast period from 2024 to 2033.

[marketreports-blog]

The global oncology molecular diagnostic market is valued at USD 2.45 billion in 2023 and is projected to reach a value of USD 7.71 Billion by 2032 at a CAGR (Compound Annual Growth Rate) of 12.20% between 2024 and 2033

[ecomehdi]

Unveiling the Battle Against Pancreatic Cancer: HDAC Inhibitors in Focus 2023

Welcome to the fascinating realm of battling Pancreatic cancer, where scientific warriors are deploying innovative strategies against a formidable foe. In this journey, we delve into the promising domain of HDAC Inhibitors and their extraordinary potential in piercing through the fibrotic shield that often obstructs conventional treatments. Understanding Pancreatic Cancer Let’s begin our…

[market-insider]

Liquid Biopsy: Evolving Trends in Breast Cancer

The global breast cancer liquid biopsy market size is expected to reach USD 1.7 billion by 2030, expandingat a CAGR of 22.7% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising preference for non-invasive methods, rising awareness of early diagnosis and treatment, and rising prevalence of breast cancer. For instance, according to WHO, in 2020, globally, 685,000 women lost their lives to breast cancer, and 2.3 million women were affected by it. Liquid biopsies have been suggested as a revolutionary technique for the early identification of breast cancer, which boosts its adoption and spurs growth. With the increasing prevalence of breast cancer, there is a high demand to provide proper diagnostics tools for detecting cancer at an early stage and early treatment.

Breast Cancer Liquid Biopsy Market Report Highlights

In 2021, the circulating tumor cells segment held a dominant revenue share owing to the effectiveness and precision offered by CTCs in the detection of cancer

The early detection segment is projected to grow at the fastest CAGR over the forecast period, owing to the increasing adoption of liquid biopsy in early diagnosis of cancer and the rising need to provide effective treatment

Treatment selection was the highest revenue-generating segment in 2021 owing to the availability of a high number of products that aid treatment selection

Asia Pacific is expected to witness the fastest growth during the forecast period owing to increasing prevalence, improving healthcare infrastructure, and growing population

Gain deeper insights on the market and receive your free copy with TOC now @: Breast Cancer Liquid Biopsy Market Report

There has been increasing R&D in the field of diagnostics to cater to the rising demand. For instance, in June 2022, according to study findings from BioFluidica, patients with HER2-positive breast cancer had success rates while receiving tailored HER2-directed therapy.The clinical significance of liquid biopsy is becoming more well-known as a result of ongoing developments in related fields. Additional interventional clinical trials and the creation of an algorithm to properly combine circulating biomarkers are required to make these technologies widely accessible.

A less intrusive technique for identifying non-hematological malignancies has been developed as a result of technological breakthroughs in continuing research on circulating biomarkers. Compared to traditional tumor biopsy, liquid biopsy is thought to be a promising option for patient monitoring in real time. For instance, in April 2022, Epic Sciences, Inc., launched DefineMBC, a blood test based on liquid biopsy technology for the diagnosis of metastatic breast cancer to its CLIA laboratory portfolio.

[literaturepublishersjournal]

Clinical Images and Case Reports Journal 

About Journal

Clinical Images and Case Reports Journal (CICRJ) is a peer-reviewed indexed medical journal established Internationally which provides a platform to publish Clinical Images, Medical Case Reports, Clinical Case Reports, Case Series (series of 2 to 6 cases), Research and Clinical Videos in Medicine. Clinical image journal is a indexed journal accepting clinical images submission, journal of clinical images, journals publishing clinical images in medicine, clinical imaging submission journal and medical illustrations etc. Journal of clinical case reports publishes case reports in clinical medicine, clinical reports, journals accepting clinical case reports submission and journal of clinical cases. Journal of medical case reports publishing medical case reports, journals accepting medical case reports submission etc.